[炎症在糖尿病多发神经病变发展中的作用及其纠正的可能性]。

Q3 Medicine
L A Shchepankevich, M A Pervuninskaya, I A Gribacheva, T F Popova, Yu A Nicolaev, E V Taneeva, E V Petrova, M S Shchepankevich
{"title":"[炎症在糖尿病多发神经病变发展中的作用及其纠正的可能性]。","authors":"L A Shchepankevich,&nbsp;M A Pervuninskaya,&nbsp;I A Gribacheva,&nbsp;T F Popova,&nbsp;Yu A Nicolaev,&nbsp;E V Taneeva,&nbsp;E V Petrova,&nbsp;M S Shchepankevich","doi":"10.17116/jnevro202312304168","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To study the effect of the combined drug Cytoflavin on the mechanisms of nonspecific inflammation in the treatment of diabetic polyneuropathy (DPN) with an assessment of the dynamics of the TNF-α index.</p><p><strong>Material and methods: </strong>An open comparative prospective observation of patients with a history of DPN for more than 5 years and a high level of TNF-α was carried out. All patients underwent basic oral combined hypoglycemic therapy, the main group used the combined drug Cytoflavin 10 ml (per 200 ml 0.9% NaCl) for 10 days, followed by the transition to the enteral form of the drug, 2 tablets 2 times a day for 1 months The main indication for the appointment of Cytoflavin was the presence of comorbid pathology in the form of cerebrovascular disease in all studied patients. The severity of clinical symptoms of DPN, the quality of life (QOL) of patients, as well as the dynamics of the level of TNF-α as an indicator reflecting the process of inflammation were assessed.</p><p><strong>Results: </strong>As a result of the treatment in the study group, there was an improvement in QoL, a decrease in the severity of sensory complaints and a decrease in the level of TNF-α, which may indicate a possible anti-inflammatory mechanism of the combined drug Cytoflavin.</p><p><strong>Conclusion: </strong>Cytoflavin can inhibit inflammation and reduce the severity of sensitive disorders in patients with DPN.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The role of inflammation in the development of diabetic polyneuropathy and the possibility of its correction].\",\"authors\":\"L A Shchepankevich,&nbsp;M A Pervuninskaya,&nbsp;I A Gribacheva,&nbsp;T F Popova,&nbsp;Yu A Nicolaev,&nbsp;E V Taneeva,&nbsp;E V Petrova,&nbsp;M S Shchepankevich\",\"doi\":\"10.17116/jnevro202312304168\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To study the effect of the combined drug Cytoflavin on the mechanisms of nonspecific inflammation in the treatment of diabetic polyneuropathy (DPN) with an assessment of the dynamics of the TNF-α index.</p><p><strong>Material and methods: </strong>An open comparative prospective observation of patients with a history of DPN for more than 5 years and a high level of TNF-α was carried out. All patients underwent basic oral combined hypoglycemic therapy, the main group used the combined drug Cytoflavin 10 ml (per 200 ml 0.9% NaCl) for 10 days, followed by the transition to the enteral form of the drug, 2 tablets 2 times a day for 1 months The main indication for the appointment of Cytoflavin was the presence of comorbid pathology in the form of cerebrovascular disease in all studied patients. The severity of clinical symptoms of DPN, the quality of life (QOL) of patients, as well as the dynamics of the level of TNF-α as an indicator reflecting the process of inflammation were assessed.</p><p><strong>Results: </strong>As a result of the treatment in the study group, there was an improvement in QoL, a decrease in the severity of sensory complaints and a decrease in the level of TNF-α, which may indicate a possible anti-inflammatory mechanism of the combined drug Cytoflavin.</p><p><strong>Conclusion: </strong>Cytoflavin can inhibit inflammation and reduce the severity of sensitive disorders in patients with DPN.</p>\",\"PeriodicalId\":24030,\"journal\":{\"name\":\"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17116/jnevro202312304168\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/jnevro202312304168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨联合用药细胞黄素对糖尿病多发神经病变(DPN)非特异性炎症发生机制的影响,评价其TNF-α指数的动态变化。材料与方法:对具有5年以上DPN病史且TNF-α水平较高的患者进行开放性比较前瞻性观察。所有患者均接受基础口服联合降糖治疗,主要组采用联合用药Cytoflavin 10 ml(每200 ml 0.9% NaCl)连用10天,随后转为肠内用药,2片,每天2次,连用1个月。评估DPN临床症状的严重程度、患者的生活质量(QOL)以及反映炎症过程的TNF-α水平的动态变化。结果:研究组经治疗后,患者生活质量改善,感觉主诉严重程度减轻,TNF-α水平下降,提示联合用药Cytoflavin可能具有抗炎作用机制。结论:细胞黄素能抑制DPN患者的炎症反应,降低敏感性疾病的严重程度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[The role of inflammation in the development of diabetic polyneuropathy and the possibility of its correction].

Objective: To study the effect of the combined drug Cytoflavin on the mechanisms of nonspecific inflammation in the treatment of diabetic polyneuropathy (DPN) with an assessment of the dynamics of the TNF-α index.

Material and methods: An open comparative prospective observation of patients with a history of DPN for more than 5 years and a high level of TNF-α was carried out. All patients underwent basic oral combined hypoglycemic therapy, the main group used the combined drug Cytoflavin 10 ml (per 200 ml 0.9% NaCl) for 10 days, followed by the transition to the enteral form of the drug, 2 tablets 2 times a day for 1 months The main indication for the appointment of Cytoflavin was the presence of comorbid pathology in the form of cerebrovascular disease in all studied patients. The severity of clinical symptoms of DPN, the quality of life (QOL) of patients, as well as the dynamics of the level of TNF-α as an indicator reflecting the process of inflammation were assessed.

Results: As a result of the treatment in the study group, there was an improvement in QoL, a decrease in the severity of sensory complaints and a decrease in the level of TNF-α, which may indicate a possible anti-inflammatory mechanism of the combined drug Cytoflavin.

Conclusion: Cytoflavin can inhibit inflammation and reduce the severity of sensitive disorders in patients with DPN.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Medicine-Psychiatry and Mental Health
CiteScore
0.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信